Medicinal Chemistry Research

, Volume 26, Issue 7, pp 1397–1404 | Cite as

6-Substituted nicotinic acid analogues, potent inhibitors of CAIII, used as therapeutic candidates in hyperlipidemia and cancer

  • Haneen K. Mohammad
  • Muhammed H. Alzweiri
  • Mohammad A. Khanfar
  • Yusuf M. Al-Hiari
Original Research


Nicotinic acid has been reported as a potential inhibitor of carbonic anhydrase III enzyme. Carbonic anhydrase III (CAIII) is an emerging new pharmacological target for the management of dyslipidemia and cancer progression. The activity of 6-substituted nicotinic acid analogs against carbonic anhydrase III was studied using a size-exclusion chromatography. The appearance of concentration-dependent vacancy peak was indicative of binding with CAIII. Chromatographic and docking studies revealed that the carboxylic acid of ligand is essential for binding via coordinate bond formation with Zn+2 ion in the enzyme active site. Moreover, the presence of a hydrophobic group, containing a hydrogen bond acceptor, at position 6 of the pyridine improves activity, e.g., 6-(hexyloxy) pyridine-3-carboxylic acid (Ki = 41.6 µM). Utilizing the weak esterase activity of CAIII, the inhibitory mode of 6-substituted nicotinic acid was confirmed.


Nicotinic acid QSAR Carbonic anhydrase Esterase 



Part of this research was conducted during the sabbatical year granted to Dr. Muhammed Alzweiri by the University of Jordan in the academic year 2015/2016.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. Alzweiri M, Al-Balas Q, Al-Hiari Y (2015) Chromatographic evaluation and QSAR optimization for benzoic acid analogues against carbonic anhydrase III. J Enzyme Inhib Med Chem 30:420–429Google Scholar
  2. Alzweiri M, Al-Hiari Y (2013) Evaluation of vanillic acid as inhibitor of carbonic anhydrase isozyme III by using a modified Hummel-Dreyer method: approach for drug discovery. Biomed Chromatogr 27:1157–1161CrossRefPubMedGoogle Scholar
  3. Berger G, Girault G (2003) Macromolecule–ligand binding studied by the Hummel and Dreyer method: current state of the methodology. J Chromatogr B 797:51–61CrossRefGoogle Scholar
  4. Busch M, Carels L, Boelens H, Kraak J, Poppe H (1997) Comparison of five methods for the study of drug–protein binding in affinity capillary electrophoresis. J Chromatogr A 777:311–328CrossRefPubMedGoogle Scholar
  5. Cabiscol E, Levine RL (1996) The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation. Proc Natl Acad Sci 93:4170–4174CrossRefPubMedPubMedCentralGoogle Scholar
  6. Dai HY, Hong CC, Liang SC, Yan MD, Lai GM, Cheng AL, Chuang SE (2008) Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway. Mol Carcinogen 47:956–963CrossRefGoogle Scholar
  7. Ginsberg HN (2006) Niacin in the metabolic syndrome: more risk than benefit? Nat Clin Pract Endocrinol Metab 2:300–301CrossRefPubMedGoogle Scholar
  8. Hassan MI, Shajee B, Waheed A, Ahmad F, Sly WS (2013) Structure, function and applications of carbonic anhydrase isozymes. Bioorgan Med Chem 21:1570–1582CrossRefGoogle Scholar
  9. Henderson LE, Henriksson D, Nyman PO (1976) Primary structure of human carbonic anhydrase C. J Biol Chem 251:5457–5463PubMedGoogle Scholar
  10. Hummel JP, Dreyer W (1962) Measurement of protein-binding phenomena by gel filtration. Biochim Biophys Acta 63:530–532CrossRefPubMedGoogle Scholar
  11. Jarrar N, Alzweiri M, Al-Hiari Y, Farah S, A Khanfar M (2015) Modified hummel–dreyer method and molecular modeling studies identified nicotinic acid analogues as carbonic anhydrase III ligands. Lett Drug Des Discov 12:401–410Google Scholar
  12. Krishnamurthy VM, Kaufman GK, Urbach AR, Gitlin I, Gudiksen KL, Weibel DB, Whitesides GM (2008) Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 108:946–1051CrossRefPubMedPubMedCentralGoogle Scholar
  13. Lindskog S, Silverman D (2000) The catalytic mechanism of mammalian carbonic anhydrases. In: Chegwidden WR, Carter N, Edwards Y (eds) The Carbonic Anhydrases. Birkhäuser Basel, Berlin, pp 175–195CrossRefGoogle Scholar
  14. Mahon BP, Mckenna R (2015) Chapter 5—carbonic anhydrase III. In: Simone CTSD (ed) Carbonic Anhydrases as Biocatalysts. Elsevier, Amsterdam, pp 91–108CrossRefGoogle Scholar
  15. Mitterberger MC, Kim G, Rostek U, Levine RL, Zwerschke W (2012) Carbonic anhydrase III regulates peroxisome proliferator-activated receptor-γ2. Exp Cell Res 318:877–886CrossRefPubMedPubMedCentralGoogle Scholar
  16. Ren X, Jonsson B-H, Lindskog S (1991) Some properties of site-specific mutants of human carbonic anhydrase II having active-site residues characterizing carbonic anhydrase III. Eur J Biochem 201:417–420CrossRefPubMedGoogle Scholar
  17. Roy P, Reavey E, Rayne M, Roy S, Abed El Baky M, Ishii Y, Bartholomew C (2010) Enhanced sensitivity to hydrogen peroxide‐induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III. FEBS J 277:441–452CrossRefPubMedGoogle Scholar
  18. Sebille B, Zini R, Madjar C-V, Thuaud N, Tillement J-P (1990) Separation procedures used to reveal and follow drug—protein binding. J Chromatogr B Biomed Sci Appl 531:51–77CrossRefGoogle Scholar
  19. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168–181CrossRefPubMedGoogle Scholar
  20. Tu C, Thomas HG, Wynns GC, Silverman DN (1986) Hydrolysis of 4-nitrophenyl acetate catalyzed by carbonic anhydrase III from bovine skeletal muscle. J Biol Chem 261:10100–10103PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Haneen K. Mohammad
    • 1
  • Muhammed H. Alzweiri
    • 1
  • Mohammad A. Khanfar
    • 1
  • Yusuf M. Al-Hiari
    • 1
  1. 1.Department of Pharmaceutical Sciences, Faculty of PharmacyThe University of JordanAmmanJordan

Personalised recommendations